MedPath

REDUCE Trial- Reducing Prolapse Recurrence

Not Applicable
Recruiting
Conditions
Prolapse; Female
Interventions
Procedure: Posterior colpoperineorrhaphy
Registration Number
NCT04880239
Lead Sponsor
Northwestern University
Brief Summary

This study will examine whether surgeons should add a prophylactic posterior colpoperineorrhaphy to a mesh-augmented apical prolapse repair.

Detailed Description

The decision to perform a posterior colpoperineorrhaphy at the time of sacrocolpopexy is controversial. Based on cohort data, some surgeons advocate that sacrocolpopexy alone is effective at treating posterior vaginal wall prolapse and the addition of posterior colpoperineorrhaphy only increases the likelihood of pain with defecation and dyspareunia. Experts theorize that placement of posterior vaginal mesh down to the perineal body provides adequate posterior support and reduces genital hiatus size. Others argue that placement of mesh too low on the posterior vagina may be associated with increased mesh exposure and pain secondary to mesh stiffness. No randomized trials exist comparing prolapse outcomes using new, ultra-light polypropylene mesh with and without posterior colpoperineorrhaphy. The investigators hypothesize that there will be no difference in prolapse outcomes after sacrocolpopexy using Restorelle mesh with and without posterior colpoperineorrhaphy. However, patients with a posterior colpoperineorrhaphy will be more likely to report pain with defecation and dyspareunia. This will be the first multicenter randomized trial comparing outcomes of sacrocolpopexy with and without posterior colpoperineorrhaphy.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
200
Inclusion Criteria
  • Women over the age of 18
  • English or Spanish speaking
  • Symptomatic prolapse (stage II or greater) undergoing minimally-invasive sacrocolpopexy with Restorelle ultra lightweight mesh
  • Preoperative genital hiatus with valsalva/strain greater than or equal to 4cm
Exclusion Criteria
  • Patient has had prior prolapse surgery
  • Patient has inflammatory bowel disease (Crohn's, Ulcerative Colitis)
  • Baseline dyspareunia (patient reports that they have pain with vaginal intercourse when asked as a yes/no)
  • Patients with a score of 7 or greater in any one muscle on the Meister Pelvic Floor Exam
  • Patient planning a concomitant Burch procedure
  • Pregnant

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sacralcolpopexy with posterior colpoperineorrhaphyPosterior colpoperineorrhaphy-
Primary Outcome Measures
NameTimeMethod
Pelvic Organ Prolapse Quantification (POP-Q) System1 Year

The POP-Q System will be used to compare the rate of prolapse recurrence at 1 year between women undergoing a sacrocolpopexy with Restorelle mesh with and without a concomitant posterior colpoperineorrhaphy.

Secondary Outcome Measures
NameTimeMethod
Surgical and Perioperative Events: Blood Loss2 Weeks

To compare the estimated blood loss (in milliliters) between groups.

Surgical and Perioperative Events: Operative TimeDay of surgery

To compare the operative time (in minutes as listed on the surgical case tracking) between groups.

Surgical and Perioperative Events: Postoperative Pain2 Weeks

To compare postoperative pain scores using a visual analog scale (0-100 points) between groups.

Surgical and Perioperative Events: Pain Medication Use2 Weeks

To compare narcotic pain medication use (in morphine equivalents consumed and reported by patients) between groups.

Defecatory Dysfunction1 Year

To compare the rates of defecatory dysfunction using the Bristol Stool Scale (stool types measured from type 1-type 7) and the Colorectal-Anal Distress Inventory 8 (measured from 0-100 points).

Dyspareunia1 Year

To compare the rates of dyspareunia between groups using the Female Sexual Function Index (measured from 2-36 points)

Trial Locations

Locations (1)

Northwestern University

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath